Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Inclusion Criteria: * Relapsed and refractory PTCL, including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) ALK+/ALK-, adult T-cell leukemia/lymphoma (ATLL), NK-cell lymphoma (NKL), transformed MF to large cell, and PTCL-unspecified (PTCL-U) patients who have failed standard therapy/transplant for their histological confirmed disease or who are not transplant eligible are eligible to participate in this trial * Karnofsky performance status \>= 70 * ANC \>= 700 cells/mm\^3, unless due to lymphoma involvement of the bone marrow or spleen * Platelet count \>= 50 mm\^3, unless due to lymphoma involvement of the bone marrow or spleen * Hemoglobin \>= 8 g/dL, unless due to lymphoma involvement of the bone marrow * Liver functions (AST, ALT, bilirubin) =\< 3 x upper limits of normal (ULN) unless due to lymphoma or due to Gilberts disease * Serum creatinine \< 2.0 mg/dL or calculated creatinine clearance (CrCl) \> 40 mL/min (Cockcroft-Gault) * LVEF \>= 40% 2-D transthoracic ECHO is the preferred method of evaluation; MUGA scan is acceptable if ECHO is not available * Able to adhere to the study visit schedule and other protocol requirements * Patients must be willing to give written informed consent, and sign an institutionally approved consent form before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical car…